Vanguard Group’s Enveric Biosciences ENVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,213
| Closed | -$6.52K | – | 4285 |
|
|
2024
Q4 | $6.52K | Hold |
1,213
| – | – | ﹤0.01% | 4287 |
|
|
2024
Q3 | $8.63K | Hold |
1,213
| – | – | ﹤0.01% | 4330 |
|
|
2024
Q2 | $11.4K | Hold |
1,213
| – | – | ﹤0.01% | 4386 |
|
|
2024
Q1 | $18.2K | Hold |
1,213
| – | – | ﹤0.01% | 4398 |
|
|
2023
Q4 | $23.7K | Buy |
1,213
+12
| +1% | +$234 | ﹤0.01% | 4431 |
|
|
2023
Q3 | $42.9K | Buy |
1,201
+367
| +44% | +$13.1K | ﹤0.01% | 4428 |
|
|
2023
Q2 | $42.2K | Buy |
834
+26
| +3% | +$1.32K | ﹤0.01% | 4477 |
|
|
2023
Q1 | $20.2K | Sell |
808
-154
| -16% | -$3.85K | ﹤0.01% | 4528 |
|
|
2022
Q4 | $30K | Hold |
962
| – | – | ﹤0.01% | 4477 |
|
|
2022
Q3 | $61K | Sell |
962
-52
| -5% | -$3.3K | ﹤0.01% | 4530 |
|
|
2022
Q2 | $163K | Hold |
1,014
| – | – | ﹤0.01% | 4491 |
|
|
2022
Q1 | $251K | Hold |
1,014
| – | – | ﹤0.01% | 4504 |
|
|
2021
Q4 | $707K | Buy |
1,014
+353
| +53% | +$246K | ﹤0.01% | 4358 |
|
|
2021
Q3 | $1.03M | Buy |
661
+419
| +173% | +$650K | ﹤0.01% | 4240 |
|
|
2021
Q2 | $432K | Buy |
242
+1
| +0.4% | +$1.79K | ﹤0.01% | 4293 |
|
|
2021
Q1 | $556K | Buy |
241
+225
| +1,406% | +$519K | ﹤0.01% | 4116 |
|
|
2020
Q4 | $52K | Buy |
+16
| New | +$52K | ﹤0.01% | 4179 |
|
|
2019
Q4 | – | Sell |
-2
| Closed | -$31K | – | 4127 |
|
|
2019
Q3 | $31K | Hold |
2
| – | – | ﹤0.01% | 4110 |
|
|
2019
Q2 | $60K | Buy |
+2
| New | +$60K | ﹤0.01% | 4092 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4116 |
|